GH exerts pleiotropic effects on growth and metabolism through the GH receptor. A deficiency in the GH receptor gene is thus associated with GH resistance and dwarfism. Complete GH resistance in humans, or Laron syndrome, has been associated with numerous inherited defects in the GH receptor, including point mutations, complete or partial gene deletions, and splice site alterations. Analysis of the GH receptor genes of these patients has provided considerable insight into structure-function relationships of the GH receptor. However, the relative rarity of this disease and the obvious difficulties involved in human research have prompted a search for an animal model of GH resistance. Numerous models have been proposed, including the sex-linked dwarf chicken, the guinea pig, and the Laron mouse. In this review, the characteristics and etiology of Laron syndrome and these animal models will be discussed. The insight provided by these disorders into the roles and mechanism of action of GH will also be reviewed.
Introduction
Growth hormone (GH) exerts pleiotropic effects on growth and metabolism through the GH receptor (GHR) (Isaakson et al. 1985) . The GHR consists of an extracellular GH-binding domain, a transmembrane domain, and an intracellular domain involved in signal transduction (Kelly et al. 1994) . GH action requires dimerization of two receptors with a single GH moiety and subsequent activation of a complex cascade of tyrosine kinases (Argetsinger & Carter-Su 1996) . GH action is modified by the soluble GH-binding protein (GHBP), which can enhance GH action by prolonging the GH half-life or can inhibit GH action (at least in vitro) by sequestering available GH (Baumann 1995) . GHBPs are thought to be produced from the GHR gene, by alternate splicing of GHR gene transcripts (in rats and mice) or by proteolytic cleavage of GHRs (humans and rabbits) (Barnard & Waters 1997) .
Our understanding of the structure and function of the GHR has recently been facilitated by the analysis of GH-resistant disorders. For instance, analysis of the GHR gene in humans suffering from complete GH resistance (Laron syndrome) has provided considerable insight into structure-function relationships of the GHR. The relative rarity of this disease and the obvious technical and ethical difficulties involved in human research has prompted a search for an animal model of GH resistance. In this review, the characteristics and etiology of human GH resistance and several animal models of GH resistance will be discussed. The insight provided by these different models into the roles and mechanism of action of GH will also be reviewed.
Laron syndrome

Characteristics
Laron syndrome (originally called Laron-type dwarfism) was first described in 1966 as 'genetic pituitary dwarfism with high serum concentration of growth hormone ' (Laron et al. 1966) . Numerous independent populations of Laron syndrome patients have since been identified in Europe, Africa, North and South America, and Asia, and the etiology and characteristics of this disease have been extensively reviewed (Rosenfeld et al. 1994 , Laron 1995 , Woods & Savage 1996 , Johnston et al. 1998 . This disorder phenotypically resembles GH deficiency, as it is characterized by severe growth retardation and insulin-like growth factor-I (IGF-I) deficiency (Rosenfeld et al. 1994) . These patients may also demonstrate the metabolic consequences of GH deficiency, including truncal obesity, delayed puberty, and hypoglycemia, despite normal or elevated serum concentrations of biologically active GH (Rosenfeld et al. 1994) . Laron syndrome is also traditionally associated with dysmorphic facial features; however, many GH-resistant patients show normal facial appearance ( Johnston et al. 1998) . The large amount of variation in Laron patients with the same genetic lesion has led Woods et al. (1997) to conclude that environmental factors and/or genetic factors other than the GHR mutation must contribute to the Laron syndrome phenotype.
Etiology
Individuals with Laron syndrome are highly responsive to the growth-promoting and metabolic effects of IGF-I but are unresponsive to exogenous GH (Rosenfeld et al. 1994 , Carel et al. 1996 , thus implicating a defect in the GHR. Indeed, more than 30 different mutations in the GHR gene have been identified, including deletion, frameshift, nonsense, missense, and splicing defects (Amselem et al. 1996 , Baumbach et al. 1997 , Parks et al. 1997 , Sobrier et al. 1997 . The diagnosis of Laron syndrome has usually been based on the absence of serum GH-binding activity; thus most identified mutations (Table 1) result from major deletions, frame-shift mutations, splicing defects, missense mutations, or nonsense mutations that abolish the binding ability of both the receptor and the binding protein (Parks et al. 1997) . Missense mutations resulting in Laron syndrome usually occur in residues participating in the GHbinding site (Sobrier et al. 1997) ; however, Walker et al. (1998) recently identified an equally deleterious point mutation that altered the intradomain angle of the extracellular binding region of the GHR. These GHBP-negative forms of Laron syndrome are generally not penetrant in the heterozygotic state, but growth and serum GHBP levels are reduced in some heterozygotes with mutations in the GHbinding domain of the GHR gene (Goddard et al. 1997) . Several compound heterozygotes have, however, been identified with severe GHBP-negative GH insensitivity (Goddard et al. 1997 , Kaji et al. 1997 . A defect in GHR mRNA regulation could also theoretically result in GHBP-negative Laron syndrome. This possibility has been postulated to account for impaired growth in African pygmies, since GHBP levels are relatively normal in young pygmies but do not undergo the normal pubertal increase (Merimee et al. 1990 , Merimee 1992 . Sequence analysis of the pygmy GHR gene has, however, revealed only an intronic mutation of unknown significance (Merimee 1992) .
Atypical (GHBP-positive) forms of Laron syndrome have recently been reported in several independent Laron syndrome populations. For instance, a point mutation in the splice donor (Woods et al. 1996b) or splice acceptor (Silbergeld et al. 1997 ) site of exon 8 results in a GHR lacking transmembrane and intracellular domains but with a normal GH-binding domain (Table 1 ). These GHRs cannot be tethered to the plasma membrane and are thus released into the circulation, resulting in high serum GH-binding activity despite GH resistance. Heterozygotic relatives of the affected families are not GH resistant, but often manifest abnormally high serum GH-binding activity (Silbergeld et al. 1997) . Mutations in other GHBP-positive Laron syndrome cohorts block receptor dimerization (Duquesnoy et al. 1994) , STAT 5 activation (Freeth et al. 1998) , IGF-I production (Woods et al. 1996a) , or putatively the interaction between the GHR and signaling molecules (Thanakitcharu et al. 1997) . GHBPs themselves were postulated to cause GH resistance in one GH-resistant cohort (Rieu et al. 1993 ). This hypothesis was based on the ability of recombinant GHBPs to inhibit GH action in vitro by sequestering available GH (Lim et al. 1990 , Mannor et al. 1991 . The excess GHBPs in this group may, however, simply reflect a defect outside the GH-binding region that blocks GH action and removes GH-induced GHR/GHBP down-regulation (Merimee et al. 1990) . Two mutations in the intracellular domain of the GHR have recently been reported that result in an autosomal dominant, GHBP-positive form of Laron syndrome (Ayling et al. 1997 , Iida et al. 1998 . Both splice-site mutations result in the deletion of exon 9 and a premature stop codon, thus the receptor protein will have normal GH-binding and transmembrane domains but will lack intracellular signaling domains such as Box 1 and Box 2 (Ayling et al. 1997 , Iida et al. 1998 . This truncated GHR isoform is also synthesized in very small amounts by alternate splicing of the normal GHR gene and can produce GH-binding proteins (Ross et al. 1997) . It also dimerizes with full-length receptors and inhibits GH signaling (Ross et al. 1997) , thus its increased production caused by the splice-site mutation would cause GH resistance in heterozygotic patients (Iida et al. 1998) .
Partial GH resistance
The mutations previously described result in complete GH resistance, but other mutations have been shown to result in partial GH resistance, in terms of a quantitative decrease in GH binding and GH responsiveness (Amselem et al. 1996) . For instance, mutations in the extracellular domain, resulting in low GHBP levels, and mutations in the intracellular domain, resulting in normal GHBP levels, are associated with varying degrees of partial GH resistance. Partial GH resistance may also account for a small proportion of children with idiopathic short stature (Goddard et al. 1997) .
Implications
Laron syndrome is thus a highly heterogeneous disorder. Although numerous defects resulting in complete GH resistance and GHBP deficiency have been identified, it is likely that many cases of GHBP-positive Laron syndrome and partial GH resistance have been overlooked and the frequency of these disorders will increase. The analysis of the genetic defects in various Laron syndrome cohorts provides necessary information for genetic counseling as well as providing clinical insight into possible therapies. In vitro analysis of missense mutations in particular has also provided crucial insight into structure-function relationships of the GHR and the importance of receptor dimerization in GH function. However, the long life-span of humans and the impossibility of human experimentation necessitates the use of animal models of GH resistance. As discussed below, GH-resistant cohorts of GH-responsive species such as the sex-linked dwarf (SLD) chicken and the Laron mouse have provided additional insight into clinical and basic questions regarding GH physiology and pathophysiology.
Sex-linked dwarfism
Characteristics
The SLD chicken is perhaps the best characterized animal model of GH resistance, and was the first model of Laron syndrome to be proposed (Hull et al. 1993b , Scanes et al. 1993 . This disorder is due to a recessive gene (dw) on the Z chromosome, and results in a significant (30-40%) reduction in body weight (Guillaume 1976 , TixierBoichard et al. 1989 , Decuypere et al. 1991 . SLD chickens also demonstrate other signs of GH deficiency, including physical alterations such as increased adiposity and endocrine abnormalities such as reduced IGF-I and tri-iodothyronine (Scanes et al. 1983 , Decuypere et al. 1991 . The pituitary GH gene is, however, normally transcribed in these birds (Leung et al. 1984) , resulting in normal or even supranormal circulating levels of GH that is indistinguishable immunologically, electophoretically, and biologically from normal GH (Hoshino & Suzuki 1982 , Harvey et al. 1984 , Hull et al. 1993b . The inability of exogenous GH to stimulate growth or IGF-I synthesis in SLDs (Bowen et al. 1987 , Huybrechts et al. 1987 suggested that sex-linked dwarfism, like Laron syndrome, might be an inherited form of GH resistance resulting from a GH receptor dysfunction. Like Laron syndrome, this disorder has arisen independently in several chicken populations and a variety of lesions in the GHR have been implicated (Table 1) .
Etiology
GH-binding sites are generally deficient in dwarf broiler and layer birds, although the degree of binding varies between <1% and 50% of control levels (Leung 1987) . The low level of GH binding suggests a defect in the GHR gene. GHR transcripts of 4·3 kb, 3·2 kb and 0·8 kb are present in the normal avian liver, resulting from the use of three different polyadenylation signals (Huang et al. 1993 , Oldham et al. 1993 . The 4·3 kb (the major GHRencoding transcript) and 3·2 kb transcripts contain identical coding regions, whereas the 0·8 kb transcript uses a polyadenylation signal in exon 5 and thus lacks residues crucial for GH binding (Huang et al. 1993 , Oldham et al. 1993 . The 4·3 kb and 3·2 kb GHR-encoding transcripts are, however, replaced by a single 2·6 kb transcript in the Connecticut strain of SLDs (Burnside et al. 1991 , Agarwal et al. 1994 . This altered transcript results from a 1·7 kb deletion of the carboxy-terminus, the stop codon, and the upstream polyadenylation signal used to produce the 3·2 kb transcript in the GHR gene (Agarwal et al. 1994) . The truncated 2·6 kb transcript is translated, as shown by Western analysis, but the resulting proteins are incapable of binding GH. The authors have thus suggested that receptor folding or insertion into the plasma membrane is adversely affected by this deletion outside the GH-binding domain.
Conversely, GHR transcripts of normal size were detected in Cornell Leghorn SLDs (Hull et al. 1992 (Hull et al. , 1993a , thus indicating that SLD, like Laron syndrome, is a heterogenous disorder. More recent analysis has revealed a T-C substitution at position 370 that would result in a phenylalanine-serine substitution at amino acid 112 (Hull et al. 1995) . A point mutation has similarly been implicated in the dwarfism of an independent Leghorn strain of SLDs, in which a G-to-T transversion results in the substitution of a serine with an isoleucine in the critically conserved WS-like motif, close to the junction between the extracellular and transmembrane domains. This mutation was shown to affect GH binding and receptor trafficking (Duriez et al. 1993) .
A point mutation has also been detected in the GHR of the Georgia strain of SLDs; however, this point mutation affects splice-site usage rather than the structural characteristics of the receptor (Huang et al. 1993) . As a result, the major 4·3 kb GHR transcript is not observed, although the 0·8 kb transcript is more abundant. This shift in transcription is due to a T to C conversion at the exon 5/intron 5 junction that eliminates a splice consensus site. The retained intron contains consensus sequences for transcript destabilization (AUUUA), thus the full-length GHR transcript would be highly unstable. However, the truncated 0·8 kb transcript would be unaffected, as it is truncated prior to intron 5. The same mutation was later identified in a completely independent strain (the Gifu strain) of SLDs (Tanaka et al. 1995) . IGF-I expression was completely abolished in these birds, suggesting that hepatic IGF-I in chickens is GH dependent (Tanaka et al. 1996) . Studies in these and other dwarfs have suggested that non-hepatic IGF-I expression is, conversely, independent of GH stimulation (Huang et al. 1993 , Tanaka et al. 1995 .
Implications
The SLD chicken is not the ideal model of Laron syndrome, due to the large taxonomic difference between birds and mammals and their discrepant GH axes. The SLD will, nevertheless, continue to provide important insight into structure-function relationships of the GHR and GH physiology. For instance, Burnside and colleagues are currently using the SLD model to identify novel GH-responsive genes by mRNA differential display (Agarwal et al. 1995) . They have identified at least 75 different transcripts that are present in normal chickens but deficient in SLD chickens, suggesting that these transcripts are GH dependent (Agarwal et al. 1995) . The gene encoding one of these GH-induced transcripts (growth hormone-regulated gene 1) contains a region homologous to the GH response element of the Spi 2·1 gene, and may thus be involved in GH signal transduction. Characterization of other GH-induced genes isolated by this procedure should provide further information regarding the GH signal transduction pathway and may identify novel GH-induced proteins and/or actions. The SLD model has also been used to distinguish between GH-dependent and GH-independent IGF-I production and growth (Tanaka et al. 1996) .
Guinea pigs
Guinea pigs show abnormalities in GH responsiveness, suggesting that they may also be a good model for examining the structural and physiological interrelationship between the GHR and the GHBP.
Guinea pigs are, for instance, resistant to the growthpromoting effects of GH, since guinea pig pituitary extracts are effective growth promoters in hypophysectomized rats (Knobil & Greep 1959) but not in guinea pigs themselves (Mitchell et al. 1954 , Daughaday et al. 1986a ). Other mammalian GH preparations are similarly ineffective growth promoters in these animals (Mitchell et al. 1954 , Daughaday et al. 1986a . It is, however, possible that guinea pigs are not resistant to the metabolic effects of GH. Exogenous GH augments estrogen receptor concentration in guinea pig uterus (Bezecny et al. 1992) , alters mammary fibroblast proliferation (Sheffield & Anderson 1986) , and antagonizes insulin action (Clayton & Worden 1960) .
The resistance of guinea pigs to the growth-promoting effects of GH would suggest that these animals are growth impaired. However, guinea pig growth seems to be completely independent of GH, as it is unaffected by hypophysectomy (Mitchell et al. 1954 , Clayton & Worden 1960 , Daughaday 1992 . Fetal growth impairment is sometimes observed in these animals, but is unrelated to changes in circulating GH ( Jones et al. 1984) . Guinea pig growth appears to be controlled by the somatomedins (IGF-I and IGF-II). However, unlike other mammals, the somatomedin axis appears to be completely uncoupled from GH, since hypophysectomy or GH administration does not alter IGF-I or IGF-II concentrations (Daughaday et al. 1986b , Daughaday 1992 . The factors responsible for IGF-I induction are currently unknown, although IGF concentrations are affected by pregnancy and malnutrition (Sohlstrom et al. 1998) . Growth in guinea pigs may thus resemble several physiological and pathophysiological states in humans, including GH-deficient patients with normal IGF-I levels (Ho & Hoffman 1995) . Growth in guinea pigs may also provide a model for fetal growth, which is similarly IGF-I dependent and GH independent (Geffner 1996) .
Despite abnormalities in GH responsiveness, the hypothalamo-pituitary axis appears to be normal in guinea pigs. Abundant GRF-and somatostatin-containing neurons are present in the hypothalamus (Dube et al. 1975 , Beauvillain et al. 1977 and GH secretion is normally regulated by both factors and increased by fasting (Fairhall et al. 1990) . GH secretion in the guinea pig is also episodic and similar to that in the rat, with large pulses at 3-4 h intervals in males and smaller pulses in females (Gabrielsson et al. 1990) . Partial characterization of guinea pig GH has shown a similarity in overall composition and a close homology of the N-terminal portion to other mammalian GHs (Gabrielsson et al. 1990) .
The GH resistance in guinea pigs was originally thought to represent a GHR defect. Harvey & Fraser (1992) disproved this hypothesis, demonstrating that hepatic GHR mRNA and hepatic binding sites for radiolabeled ovine GH were readily detectable (Harvey & Fraser 1992) . Subsequent studies suggested that guinea pigs were deficient in serum GHBPs (Amit et al. 1992 , Fairhall et al. 1992 . However, immunological GHBPs cross-reacting with numerous GHBP antiserum (including one directed against the rat hydrophilic tail) were detected by Hull et al. (1996) . This study also reported differences in ligand specificity between hepatic and serum GH-binding sites, as serum GHBPs (unlike hepatic GHRs) could not bind ovine GH. In contrast, Ymer et al. (1997) reported that serum GHBPs were capable of binding ovine, but not human GH, and thus the ligand specificity of the two GH-binding moieties was identical. The same group has also partially cloned the guinea pig GHR (exons 2-7, representing the extracellular domain), and the major GH-binding residues are conserved, although additional glycosylation sites are present that may affect GH binding (Ymer et al. 1996) . Future cloning and expression studies should thus provide additional information regarding the riddle of the guinea pig GH resistance. Perhaps differences in the intracellular domain selectively influence the growth-promoting, but not metabolic, signal transduction pathways of the GH receptor. Kopchik et al. (1998) have recently developed a novel mammalian model of GH resistance, the GHR/GHBP knockout mouse (Table 1) . Like patients with Laron syndrome, these mice are characterized by severe postnatal growth retardation, low levels of serum IGF-I, and elevated levels of serum GH (Kopchick 1998). GH and IGF-I were not altered in heterozygotic mice, although growth in females was slightly, but significantly, impaired (Zhou et al. 1997) . GHR mRNA and GHBP mRNA are undetectable in the kidney or liver of these mice. The phenotypic characteristics of this model remain to be established, although a preliminary report has identified decreased litter size and increased newborn mortality as well as a mild impairment of glucose tolerance in the homozygous GHR-deficient mice (Coschigano et al. 1998) . Sexual maturation was delayed and litter size was decreased, and newborn mortality was increased, perhaps due in part to reduced lactation (Zhou et al. 1997) . Neither birth weight nor behavior was affected (Zhou et al. 1997) . Although GHR mRNA was undetectable, small amounts of GH-binding activity were detected in the liver and kidney (Zhou et al. 1997) . The severe growth impairment in these knockout mice would negate the possibility that this binding activity is involved in somatic growth, but it could putatively reflect the presence of a novel GHR that mediates metabolic, rather than somatic effects of GH.
The Laron mouse
The Laron mouse is easily the best model of GH resistance thus far identified. It is obviously mammalian, homogenous, and is not complicated by additional, uncharacterized endocrine disorders such as the guinea pig. This model should prove extremely useful to answer both clinical and basic questions. For instance, the short life-span of the mouse would facilitate the analysis of chronic effects of IGF-I treatment on long-term processes such as aging and tumorigenesis. The Laron mouse would also be an invaluable tool to investigate paracrine, intracrine, and autocrine effects of GH. It has been hypothesized (Harvey & Hull 1997) that GH action in some tissues is mediated by local, rather than endocrine, actions of GH. Studies of GH action in these non-traditional target sites such as immune and reproductive organs are thus hampered by local production of GH that saturates receptors. The gene-knockout mouse could permit the restoration of selective responsiveness in particular tissues, since modified Laron mouse strains could be engineered in which a functional GHR gene is coupled to a tissuespecific promoter.
Other mammalian models
Dwarfed strains of pigs, poodles, and Brahmin cattle have received minimal attention as potential models of GH resistance (Daughaday 1992) ( Table 1 ). All three animals exhibit the characteristics of GH resistance, including impaired IGF-I concentrations and growth retardation despite normal or supranormal GH concentrations (Daughaday 1992) . Plasma GHBP activity in dwarf poodles and cattle are normal, suggesting a defect in the intracellular or transmembrane domains of the receptor or in postreceptor mechanisms (Lauterio et al. 1988 , Hammond & Olson 1991 . Conversely, GHBPs are deficient in miniature pigs, implicating a dysfunction in the extracellular domain of the GHR (Lauterio et al. 1988) . Although pigs, cattle and poodles are not ideal laboratory animals, miniature poodles and cattle are currently the only available model of GHBP-positive GH resistance.
Summary
The complexity of the GH signaling pathway, the ubiquitousness of GH target sites and the multiple sites of GH production have hampered our understanding of GH physiology. The analysis of GH-resistant human and animal populations has already provided considerable insight into the structure and roles of the GHR, and newly developed animal models such as the Laron mouse should prove extremely valuable in future studies. 
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